Diego Rotsztain Sold 3,184 Shares of GAIN Capital Holdings, Inc. (GCAP); 5 Bullish Analysts Covering Fibrocell Science, Inc. (FCSC)

May 9, 2018 - By Hazel Jackson

Fibrocell Science, Inc. (NASDAQ:FCSC) Logo

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 13 analyst reports since September 28, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of FCSC in report on Tuesday, January 16 with “Buy” rating. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) earned “Buy” rating by Roth Capital on Tuesday, December 22. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. On Friday, June 9 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating given on Tuesday, January 30 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $7.6 target in Thursday, October 5 report. H.C. Wainwright maintained the shares of FCSC in report on Monday, March 19 with “Buy” rating. The rating was downgraded by Wedbush on Monday, September 28 to “Neutral”. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, September 26 report. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 6. See Fibrocell Science, Inc. (NASDAQ:FCSC) latest ratings:

19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
06/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
30/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

The stock increased 0.83% or $0.0046 during the last trading session, reaching $0.56. About 107,175 shares traded. Fibrocell Science, Inc. (NASDAQ:FCSC) has declined 72.30% since May 9, 2017 and is downtrending. It has underperformed by 83.85% the S&P500.

More important recent Fibrocell Science, Inc. (NASDAQ:FCSC) news were published by: Globenewswire.com which released: “Fibrocell Announces Review of Strategic Alternatives” on April 18, 2018, also Nasdaq.com published article titled: “Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial …”, Bizjournals.com published: “Voucher sale brings $110M payday for Spark Therapeutics” on April 30, 2018. More interesting news about Fibrocell Science, Inc. (NASDAQ:FCSC) was released by: Globenewswire.com and their article: “Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA” with publication date: April 10, 2018.

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company has market cap of $15.88 million. The companyÂ’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It currently has negative earnings. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.

GAIN Capital Holdings, Inc. provides trading services and solutions to retail, institutional, and futures service clients worldwide. The company has market cap of $366.98 million. The firm operates in three divisions: Retail, Institutional, and Futures. It currently has negative earnings. It specializes in over-the-counter and exchange-traded markets.

Among 6 analysts covering Gain Capital Holdings (NYSE:GCAP), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Gain Capital Holdings has $10 highest and $7.0 lowest target. $8.25’s average target is 0.61% above currents $8.2 stock price. Gain Capital Holdings had 18 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Thursday, August 3 with “Buy”. The stock of GAIN Capital Holdings, Inc. (NYSE:GCAP) has “Hold” rating given on Friday, March 9 by Keefe Bruyette & Woods. The stock of GAIN Capital Holdings, Inc. (NYSE:GCAP) earned “Market Perform” rating by Raymond James on Wednesday, March 16. The firm has “Buy” rating given on Wednesday, March 8 by Jefferies. The firm earned “Hold” rating on Thursday, December 21 by Keefe Bruyette & Woods. The company was maintained on Monday, October 16 by Jefferies. On Monday, July 10 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. Keefe Bruyette & Woods maintained the shares of GCAP in report on Friday, November 10 with “Hold” rating. As per Thursday, March 8, the company rating was maintained by Jefferies. The stock has “Hold” rating by Keefe Bruyette & Woods on Thursday, August 17.

Investors sentiment decreased to 1.18 in Q4 2017. Its down 0.35, from 1.53 in 2017Q3. It turned negative, as 11 investors sold GAIN Capital Holdings, Inc. shares while 34 reduced holdings. 28 funds opened positions while 25 raised stakes. 23.11 million shares or 2.62% less from 23.73 million shares in 2017Q3 were reported. Mycio Wealth Ptnrs Ltd Liability Company reported 0.02% in GAIN Capital Holdings, Inc. (NYSE:GCAP). North Amer Management Corporation invested in 11,042 shares. Public Employees Retirement Systems Of Ohio owns 21,544 shares. Weber Alan W holds 656,773 shares or 2.87% of its portfolio. Wells Fargo Mn reported 0% stake. Cornerstone Capital Management Limited Company owns 51,700 shares for 0% of their portfolio. Parallax Volatility Advisers L P accumulated 7,352 shares or 0% of the stock. Ny State Common Retirement Fund invested 0% of its portfolio in GAIN Capital Holdings, Inc. (NYSE:GCAP). Emerald Mutual Fund Advisers Tru holds 0.04% in GAIN Capital Holdings, Inc. (NYSE:GCAP) or 111,620 shares. Parametric Assoc Ltd Liability Company has 10,503 shares. Arrowstreet Partnership holds 0% or 104,782 shares. Martingale Asset Lp invested in 0.01% or 56,049 shares. Morgan Stanley invested in 0.01% or 2.08M shares. Schwab Charles Inv Management reported 0% in GAIN Capital Holdings, Inc. (NYSE:GCAP). Legal & General Gru Public Limited Liability has invested 0% in GAIN Capital Holdings, Inc. (NYSE:GCAP).

The stock decreased 0.36% or $0.03 during the last trading session, reaching $8.2. About 350,761 shares traded. GAIN Capital Holdings, Inc. (NYSE:GCAP) has declined 22.29% since May 9, 2017 and is downtrending. It has underperformed by 33.84% the S&P500.

GAIN Capital Holdings, Inc. (NYSE:GCAP) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>